NCT00471081CompletedPhase 2
Study to Assess Immunogenicity, Reactogenicity and Safety of Primary Vaccination With GSK Biologicals' MenACWY Vaccine (GSK134612) Given as 1 or 2 Doses to Healthy Toddlers 9-12 Months of Age
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- GlaxoSmithKline
- Enrollment
- 385
- Locations
- 19
- Primary Endpoint
- Number of Subjects With Serum Bactericidal Assay Using Human Complement Against Neisseria Meningitides Serogroups A, C, W-135, Y (hSBA-MenA, hSBA-MenC, hSBA-MenW -135 and hSBA-Men-Y) Antibody Titers Greater Than or Equal to the Cut-off Value
Study Overview
Brief Summary
The purpose of the study is to characterize the safety and immunogenicity of 1 dose of GSK134612 vaccine at 12 months of age and of GSK134612 vaccine administered as 2 doses at 9 and 12 months of age.
Detailed Description
The protocol posting has been amended to reflect changes as a consequence of an amendment to the protocol and also to comply with the FDA amendment Act, Sep 2007. Sections impacted are Brief Title, Official Title of the study, Brief Summary, Key Inclusion & Exclusion criteria.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 9 Months to 9 Months (Child)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subjects whose parents/guardians the investigator believes can and will comply with the requirements of the protocol
- •A male or female of 9 months of age (has not attained 10 months of age) at the time of enrollment.
- •Up to date on vaccinations based on ACIP recommendations and the standard practice at the investigational site.
- •Written informed consent obtained from parents/guardian of the subject.
- •Healthy subjects as established by medical history and clinical examination before entering into the study.
Exclusion Criteria
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding enrollment, or planned use during the study period.
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose.
- •Planned administration/ administration of a vaccine not foreseen by the study protocol within 1 month of a dose of study vaccine(s), with the exception of influenza vaccine.
- •Planned administration of a tetanus toxoid (TT) containing vaccine throughout the active phase of the study (through one month after the last vaccination).
- •Previous vaccination with meningococcal polysaccharide or conjugate vaccine of serogroup A, C W and/or Y.
- •History of meningococcal diseases.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination (no laboratory testing is required).
- •A family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.
- •History of reactions or allergic disease likely to be exacerbated by any component of the vaccine.
- •Major congenital defects or serious chronic illness.
- •History of any neurologic disorders or seizures.
- •Acute disease at the time of enrollment.
- •Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the active phase of the study (through one month after the last dose of study vaccine).
Arms & Interventions
Group A
Experimental
Single dose GSK134612.
Intervention: Meningococcal vaccine GSK134612 (Biological)
Group B
Experimental
Two doses of GSK134612.
Intervention: Meningococcal vaccine GSK134612 (Biological)
Outcomes
Primary Outcomes
Number of Subjects With Serum Bactericidal Assay Using Human Complement Against Neisseria Meningitides Serogroups A, C, W-135, Y (hSBA-MenA, hSBA-MenC, hSBA-MenW -135 and hSBA-Men-Y) Antibody Titers Greater Than or Equal to the Cut-off Value
Time Frame: One month after the last dose (at Month 4)
The cut-off value for the hSBA titers was greater than or equal to (≥) 1:8.
Secondary Outcomes
- Number of Subjects With New Onset Chronic Ilnesses (NOCI)(Up to study end (Month 9))
- Number of Subjects With Serum Bactericidal Assay Using hSBA-MenA, hSBA-MenC, hSBA-MenW -135 and hSBA-Men-Y Antibody Titers Greater Than or Equal to the Cut-off Value(At Month 1 (for GSK 134612 2 doses Group only) and Month 4)
- hSBA-MenA, hSBA-MenC, hSBA-MenW -135 and hSBA-Men-Y Antibody Titers(At Month 1 (for GSK 134612 2 doses Group only) and Month 4)
- Number of Subjects With Serum Bactericidal Assay Using Rabbit Complement Against Neisseria Meningitides Serogroups A, C, W-135, Y (rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY) Antibody Titers Greater Than or Equal to the Cut-off Value(At Month 1 (for GSK 134612 2 doses Group only) and Month 4)
- Number of Subjects With Serum Bactericidal Assay Using rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers Greater Than or Equal to the Cut-off Value(At Month 1 (GSK 134612 2 doses Group only) and Month 4)
- rSBA-MenA, rSBA-MenC, rSBA-MenW -135 and rSBA-Men-Y Antibody Titers(At Month 1 (GSK 134612 2 doses Group only) and Month 4)
- Number of Subjects With Anti-polysaccharide Meningococcal Serogroup A (Anti-PSA), Serogroup C (Anti-PSC), Serogroup W-135 (Anti-PSW-135) and Serogroup Y (Anti-PSY) Antibody Concentrations Greater Than or Equal to the Cut-off Value(At Month 1 (GSK 134612 2 doses Group only) and Month 4)
- Number of Subjects With Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations Greater Than or Equal to the Cut-off Value(At Month 1 (GSK 134612 s doses Group only) and Month 4)
- Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations(At Month 1 (GSK 134612 2 doses Group only) and Month 4)
- Number of Subjects With Any and Grade 3 Solicited Local Symptoms(During the 4-day (Days 0-3) and 8-day (Days 0-7) periods following each vaccination)
- Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms(During the 4-day (Days 0-3) and 8-day (Days 0-7) periods following each vaccination)
- Number of Subjects With Any Unsolicited Adverse Events (AEs)(Up to 1 month post-vaccination)
- Number of Subjects With Serious Adverse Events (SAEs)(Up to study end (Month 9))
- Number of Subjects Reporting Rash(Up to study end (Month 9))
- Number of Subjects Reporting Adverse Events Resulting in Emergency Room (ER) Visits(Up to study end (Month 9))
- Number of Subjects With Serum Bactericidal Assay Using hSBA-MenA, hSBA-MenC, hSBA-MenW -135 and hSBA-Men-Y Antibody Titers Greater Than or Equal to the Cut-off Value(One month after the first dose (at Month 1))
Investigators
Study Sites (19)
Loading locations...
Similar Trials
Completed
Phase 2
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.Infections, MeningococcalNCT00454909GlaxoSmithKline873
Completed
Phase 2
A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in ChildrenVirus DiseasesNCT02548078GlaxoSmithKline600
Completed
Phase 3
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal InfectionInfections, StreptococcalStreptococcus Pneumoniae VaccinesNCT01746108GlaxoSmithKline52
Completed
Phase 1
Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With FluarixInfluenzaNCT00693706GlaxoSmithKline200
Completed
Phase 3
Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in MaliInfections, StreptococcalNCT00985465GlaxoSmithKline218